Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165199 | 0.88 | CFTR (0.53) | CFTRKDM4EMAPTTLR2TLR1 | |
| SCHEMBL5166699 | 0.87 | CFTR (0.52) | CFTRKDM4EMAPTTLR2TLR1 | |
| SCHEMBL5167408 | 0.85 | CFTR (0.60) | CFTRKDM4EMAPTALDH1A1GLA | |
| SCHEMBL28761821 | 0.84 | CFTR (0.49) | CFTRKDM4EMAPTTLR2TLR1 | |
| SCHEMBL5166472 | 0.84 | CFTR (0.49) | CFTRKDM4EMAPTTLR2TLR1 | |
| SCHEMBL5167327 | 0.82 | SMN1; SMN2 (0.37) | CFTRKDM4EPDE3BMAPTTLR2 | |
| SCHEMBL5169366 | 0.82 | CFTR (0.46) | CFTRKDM4EMAPTTLR2TLR1 | |
| SCHEMBL2597278 | 0.74 | CFTR (0.53) | CFTRKDM4EMAPTALDH1A1GLA | |
| SCHEMBL5168216 | 0.74 | CFTR (0.59) | CFTRKDM4EMAPTALDH1A1GLA | |
| SCHEMBL31603104 | 0.73 | CFTR (0.68) | CFTRKDM4EMAPTALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773788-B1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1773788-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS-PHARMA GMBH (AT) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010591-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208018-A1 | Quinazoline Derivatives | CYP3A5, CYP3A7, CYP3A4 | CFTR 430/4885KDM4E 1450/4885PDE3B 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.